Navigating One’s Bio-Pharma Career through 2023’s Turbulent Job Markets
Pharmaceutical Commerce
FEBRUARY 3, 2023
Jasmin Patel of a-Connect provides insight on how to navigate the ebbs and flows of employment.
Sat.Jan 28, 2023 - Fri.Feb 03, 2023
52 
J&J's pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries
Fierce Pharma
FEBRUARY 3, 2023
J&J's pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries mbayer Fri, 02/03/2023 - 09:29
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
GoodRx Illegally Sold Users’ Data to Google & Facebook, FTC Says
MedCity News
FEBRUARY 1, 2023
GoodRx failed to notify users that it sold their personal health information to Google, Facebook and other tech companies, the FTC claimed. The agency filed an order that prohibits GoodRx from sharing its users’ data with third parties for advertising purposes and requires the company to pay a $1.5 million penalty. GoodRx agreed to pay the settlement but did not admit to wrongdoing.
HIV vaccines suffer setbacks but new approaches could turn the tide
Pharmaceutical Technology
FEBRUARY 3, 2023
Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections. This marks the second time one of Janssen’s HIV vaccines failed after another showed disappointing results in the Phase IIb Imbokodo trial in August 2021.
AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Halting Europe’s essential medicines manufacturing exodus
European Pharmaceutical Review
FEBRUARY 2, 2023
While maintaining a healthy manufacturing industry for production of ‘high tech’ pharmaceuticals, Europe has stepped away from manufacturing essential medicines and active pharmaceutical ingredients (APIs) due to unrelenting price pressures and is now heavily reliant on the import of these critical ingredients. There is now a large regional concentration in the production of generic APIs in Asia with 66 percent of the world’s API production by volume manufactured in India and China. 1 Europe is
Pfizer warns Comirnaty sales will plummet by nearly two-thirds in 2023. And Paxlovid won't fare much better
Fierce Pharma
JANUARY 31, 2023
Pfizer warns Comirnaty sales will plummet by nearly two-thirds in 2023.
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
uniQure signs license deal for Apic Bio’s gene therapy for SOD1-ALS
Pharmaceutical Technology
JANUARY 31, 2023
Gene therapy company uniQure has entered into a global licensing agreement with Apic Bio for APB-102 to treat patients with amyotrophic lateral sclerosis (ALS) caused by mutations in superoxide dismutase 1 (SOD1). Under the terms of the deal, uniQure will obtain the worldwide rights to develop and market the clinical stage gene therapy, APB-102. uniQure stated that the license of APB-102 further strengthens its gene therapies pipeline developed for the treatment of neurological disorders as well
Three-year patent strategy for greater medicine access announced
European Pharmaceutical Review
JANUARY 31, 2023
A new strategy for 2023-2025 by the Medicines Patent Pool (MPP) aims to reduce access inequities, by improving the availability and affordability of health products in low- and middle-income countries (LMICs). The MPP is a United Nations-backed public health organisation working to increase medicine access and facilitate the development of life-saving medicines for LMICs.
Amid mainstream hype, Eli Lilly takes a hard line marketing its buzzy diabetes med Mounjaro
Fierce Pharma
FEBRUARY 2, 2023
Amid mainstream hype, Eli Lilly takes a hard line marketing its buzzy diabetes med Mounjaro fkansteiner Thu, 02/02/2023 - 11:20
Why Telehealth Implementation Is Not Just a Project for IT
MedCity News
FEBRUARY 3, 2023
Telehealth implementation should be a joint responsibility of IT, administration, and providers. Otherwise, a lack of teamwork between departments leads to siloing and lots of passing the telemedicine “hot potato” among those who don’t have all the information.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
US FDA approves GSK’s Jesduvroq to treat anaemia of CKD
Pharmaceutical Technology
FEBRUARY 2, 2023
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline ’s (GSK) Jesduvroq (daprodustat) to treat anaemia caused by chronic kidney disease (CKD) in adults who have been on dialysis for at least four months. Jesduvroq is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). It is claimed to be the only HIF-PHI approved in the country that offers a new oral treatment option for adult patients on dialysis with anaemia of CKD.
Smart Walking Stick for Visually Impaired People
Medgadget
JANUARY 30, 2023
Researchers at the University of Colorado at Boulder have developed a smart walking stick that can assist blind or visually impaired people to navigate their environment, from grocery shopping to finding a seat in a busy café. The system employs cameras to visualize the environment and items within it, such as products in a supermarket, and uses AI to identify objects and provide guidance for the user.
Amgen's Humira biosimilar Amjevita hits the market with two different list prices
Fierce Pharma
JANUARY 31, 2023
Amgen's Humira biosimilar Amjevita hits the market with two different list prices zbecker Tue, 01/31/2023 - 10:58
I’m a GI Doctor. A Colon Cancer Screening Could Save Your Life.
MedCity News
JANUARY 29, 2023
A recent NEJM publication concluded that although colonoscopy is widely used as a dependable screening test to detect colorectal cancer, its overall effect on the risks of colorectal cancer death is potentially less clear than previously reported. The doubt sprouting from this study is misplaced, dangerous and will potentially lead to more deaths from this disease.
Clinical Trials Information System mandatory in EU
European Pharmaceutical Review
FEBRUARY 1, 2023
From 31 January 2023, all initial clinical trial applications in the European Union (EU) must be submitted via the Clinical Trials Information System (CTIS). According to the European Medicines Agency (EMA), CTIS is now the single-entry point for sponsors and regulators of clinical trials for the submission and assessment of clinical trial data. This follows a one-year transition, during which sponsors could choose whether to apply for a new clinical trial in the EU/EEA in line with the Clinical
Pfizer reports 30% operational growth in full-year 2022 revenues
Pharmaceutical Technology
FEBRUARY 1, 2023
Pfizer has reported a 30% operational growth in revenues to $100.3bn in full-year 2022 compared with $81.2bn reported last year. The revenues grew 2% operationally excluding Paxlovid and Comirnaty’s contributions. In the fourth quarter (Q4) of 2022, they increased 13% operationally to $24.3bn compared to $23.8bn in the same quarter last year. On an operational basis, the revenues rose by 5%, omitting contributions from Paxlovid and Comirnaty.
Menarini shows Big Pharma how it's done with first approval for oral SERD drug in breast cancer
Fierce Pharma
JANUARY 30, 2023
Menarini shows Big Pharma how it's done with first approval for oral SERD drug in breast cancer kdunleavy Mon, 01/30/2023 - 10:22
Healthcare Spent $18B More on Administrative Tasks in 2022 Than Year Prior
MedCity News
FEBRUARY 3, 2023
The U.S. healthcare system spent $60 billion on administrative tasks last year, which is about $18 billion more than it spent in 2021, according to a new report. There are a couple reasons for this — the workforce shortage and Americans’ increased utilization of healthcare services.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
France gets new sterile liquid drug manufacturing facility
European Pharmaceutical Review
FEBRUARY 3, 2023
Switzerland-based contract development and manufacturing organisation (CDMO) CARBOGEN AMCIS has opened a new facility in France, dedicated to the custom development and production of sterile injectable drug products. The facility forms two new fully-automated production lines for liquid and freeze-dried drugs, including highly potent compounds and advanced therapies such as antibody drug conjugates (ADCs).
Magazine: CRISPR gene therapies cut through in 2023
Pharmaceutical Technology
FEBRUARY 2, 2023
If things go as per plan, in a few months, the US Food and Drug Administration (FDA) will deliberate on the first-of-its-kind CRISPR-based gene therapy for sickle cell disease (SCD) and transfusion-dependent beta thalassemia. Having made significant advances in a relatively short period of time, CRISPR research is now edging closer to reaching the clinic , and this month’s cover story takes a look at the major players in this field and the big events that could break through this year.
In mysterious FDA approval, Pfizer quietly wins Ibrance breast cancer expansion
Fierce Pharma
JANUARY 31, 2023
In mysterious FDA approval, Pfizer quietly wins Ibrance breast cancer expansion aliu Tue, 01/31/2023 - 10:37
With Livongo, did Zane Burke sell a lemon to Teladoc’s Jason Gorevic?
MedCity News
JANUARY 29, 2023
Was Livongo a good business? As Burke, now CEO of Quantum Health, touts its strength to investors ahead of a potential IPO, should the Livongo-Teladoc history give them pause?
How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
GitHub is Sued, and We May Learn Something About Creative Commons Licensing
Copyright Clearance Center
JANUARY 31, 2023
This article was originally published in The Scholarly Kitchen. I have had people tell me with doctrinal certainty that Creative Commons licenses allow text and data mining, and insofar as license terms are observed, I agree. The making of copies to perform text and data mining, machine learning, and AI training (collectively “TDM”) without additional licensing is authorized for commercial and non-commercial purposes under CC BY , and for non-commercial purposes under CC BY-NC.
First medicine approved in EU for eosinophilic esophagitis
European Pharmaceutical Review
JANUARY 31, 2023
The European Commission (EC) has expanded the marketing authorisation for Dupixent® (dupilumab) in the European Union (EU) to treat eosinophilic esophagitis (EoE). It is the “… first and only targeted treatment option clinically proven to reduce both oesophageal inflammation and damage,” explained Dr Naimish Patel, Head of Global Development, Immunology and Inflammation at Sanofi.
Court rejects Johnson & Johnson's Texas two-step bankruptcy ploy for talc claims
Fierce Pharma
JANUARY 30, 2023
Court rejects Johnson & Johnson's Texas two-step bankruptcy ploy for talc claims kdunleavy Mon, 01/30/2023 - 16:24
FDA Asks Gene Therapy Biotech to Run Clinical Trial That Might Be Impossible
MedCity News
FEBRUARY 1, 2023
Taysha Gene Therapies has encouraging data from an open-label, Phase 1/2 study in the rare disease giant axonal neuropathy. It might not be enough. The FDA recommended the biotech conduct a randomized and placebo-controlled study—a challenge in any ultra-rare disease.
How to Stay Competitive in the Evolving State of Martech
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Merck reports 2% increase in worldwide sales in Q4 2022
Pharmaceutical Technology
FEBRUARY 3, 2023
Merck (MSD outside North America) has reported a 2% increase in worldwide sales to $13.83bn in the fourth quarter (Q4) of 2022 from $13.52bn in the previous year’s quarter. The company’s pharmaceutical sales recorded a 1% rise to $12.18bn compared to $12.03bn in the prior-year quarter. For the quarter, GAAP earnings per share (EPS) from continuing operations was $1.18, indicating a 22% decline from $1.5 in the same quarter last year.
First biosimilar to HUMIRA® available in US
European Pharmaceutical Review
FEBRUARY 2, 2023
AMJEVITA (adalimumab-atto), a biosimilar to Humira ® (adalimumab), is now available in the US. Amgen’s AMJEVITA was the first biosimilar to Humira approved by the US Food and Drug Administration (FDA), in 2016. The active ingredient in the anti-TNF-α monoclonal antibody has the same amino acid sequence as Humira. The Humira biosimilar will be available in prefilled syringe and autoinjector presentations to support dosing in each of the approved indications.
Following in Lilly's footsteps, Teva takes 2nd long-acting schizophrenia drug into phase 3
Fierce Pharma
JANUARY 31, 2023
Following in Lilly's footsteps, Teva takes 2nd long-acting schizophrenia drug into phase 3 ntaylor Tue, 01/31/2023 - 06:26
What Health Plans Need To Know About QHPs Now That the ACA Is Here To Stay
MedCity News
JANUARY 29, 2023
Now that numerous calls for repeal and legal challenges brought against the ACA over the years have failed, health plans can finally invest confidently in this line of business.
Let's personalize your content